Children's Hospital Los Angeles Participates in Trial Testing Novel CAR T-Cell Therapy for Children With T-Cell Leukemia

The phase 2 study is testing a novel, off-the-shelf chimeric antigen receptor (CAR) T-cell therapy called WU-CART-007. Developed by Wugen Inc., the investigational therapy uses CRISPR-Cas9 gene editing and is specifically designed for children and adults with T-cell leukemia and lymphoma.